Post by PressRelease on Oct 23, 2023 7:05am
New Press Release - Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
Comment by
Lesalpes29 on Oct 23, 2023 8:09am
In Matt we trust! If we look at the markets reaction after two NR this morning. Matt where are the deal and multiple phase 3 announcement? GL
Comment by
Azzak34 on Oct 23, 2023 8:28am
Matt doesn't control the markets you silly goose. His job is to produce strong results, which he continues to do. Communication has been poor but ONCY continues to show why they're going to get bought out.
Comment by
Lesalpes29 on Oct 23, 2023 8:37am
I love goose and moose! If you read my post I'am asking Matt to deliver DEAL and PHASE 3 as he said. Probably coming in the coming weeks and I wish it to you and me and Canadafan, Fox and others here that ge will do it! GL
Comment by
Azzak34 on Oct 23, 2023 8:43am
Then just wait. All wording and data shows it's a done deal. All we're waiting for is the announcement. Stop spreading fud and anxiety, just wait.
Comment by
Lesalpes29 on Oct 23, 2023 8:52am
Probably buy more and wait! Not going to post here until deal or phase 3 announcement to enjoy it with all the very long shareholders here. Have a very good end of 2023! GL
Comment by
Noteable on Oct 23, 2023 1:06pm
Roche to acquire Telavant for $7.1b. On the strength of biomarker data in Riovants Phase2b study , Roche is very likely looking towards filing an Accelerated Approval with the FDA for Telavant. And so it may be the same happening with the acquisition of ONCY
Comment by
Azzak34 on Oct 26, 2023 1:56pm
I just had to re-log in to my other account to post this. Azzak is Noteable???? You've never seen us in the same room together!
Comment by
Azzak34 on Oct 26, 2023 1:59pm
Great post Noteable. We spent the extra time fine tuning Pela and turning it in to a breakthrough therapy. Guess it was worth it!!
Comment by
Noteable on Oct 26, 2023 2:25pm
Yes - and a potential Accelerated Approval for the pelareorep combination which could result in pelareorep + CPI becoming a new Standard of Care (SOC) in the treatment of advanced/metastatic pancreatic cancer,given the current unmet treatment need for pancreatic cancer, and in particular for this aggressive form of pancreatic cancer.